The role of driver mutations in myeloproliferative neoplasms: insights from mouse models
K Shide - International Journal of Hematology, 2020 - Springer
High frequency of JAK2 V617F or CALR exon 9 mutations is a main molecular feature of
myeloproliferative neoplasms (MPNs). Analysis of mouse models driven by these mutations …
myeloproliferative neoplasms (MPNs). Analysis of mouse models driven by these mutations …
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”
MG Mazzucconi, E Baldacci… - European Journal of …, 2020 - Wiley Online Library
Background and aims Anagrelide is a drug effective in reducing platelet counts in essential
thrombocythemia (ET) and Ph1‐negative myeloproliferative neoplasms. The aim of this …
thrombocythemia (ET) and Ph1‐negative myeloproliferative neoplasms. The aim of this …
Napredovanje ateroskleroze, togosti arterijske stene in endotelijske disfunkcije pri bolnikih z esencialno trombocitemijo glede na obremenitev z mutacijo JAK2 V617F
A Anžič Drofenik - 2020 - repozitorij.uni-lj.si
UVOD Prezgodnja umrljivost bolnikov z esencialno trombocitemijo (ET) je v veliki meri
povezana s srčno-žilnimi boleznimi. Kljub temu do sedaj še nihče ni preučeval, kakšna je …
povezana s srčno-žilnimi boleznimi. Kljub temu do sedaj še nihče ni preučeval, kakšna je …
Ruolo di Calreticulina Wild-Type nell'emopoiesi fisiologica ed effetto delle mutazioni di Calreticulina nello sviluppo delle Neoplasie Mieloproliferative
E Genovese - 2020 - iris.unimore.it
Calreticulin (CALR) is a 46 kDa endoplasmic reticulum (ER) chaperone responsible for
intracellular calcium regulation and protein folding. CALR is also able to perform different …
intracellular calcium regulation and protein folding. CALR is also able to perform different …